FDA Approves groundbreaking drug for schizophrenia treatment
On Thursday, the U.S. Food and Drug Administration (FDA) approved the drug Cobenfy which targets schizophrenia in a new way. Cobenfy (xanomeline and trospium chloride) capsules are the first antipsychotic drug approved to target cholinergic receptors. All other treatments available for schizophrenia target the dopamine receptors.
FARGO, N.D. (Valley News Live) - Changes are coming to the way schizophrenia is treated. The US Food and Drug ...
Experts expressed enthusiasm Friday after US health regulators approved the first new form of treatment for schizophrenia in ...
From Eli Lilly to Karuna Therapeutics to current owner Bristol Myers Squibb, the newly approved schizophrenia drug had quite ...
New schizophrenia drug Cobenfy offers hope with fewer side effects targeting symptoms more effectively than traditional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback